Abbott, Astra drug combo works in cholesterol study
ORLANDO, Fla (Reuters) - A combination of Abbott Laboratories' new TriLipix triglycerides medicine and a low dose of AstraZeneca Plc's Crestor cholesterol drug proved better than the individual pills in helping improve heart risk factors, researchers said.<div class="feedflare">
<img src="http://feeds2.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA" border="0"></img> (http://feeds.reuters.com/~ff/reuters/healthNews?a=wLSynvkl-Wk:DWfhlnFh73Y:yIl2AUoC8zA) <img src="http://feeds2.feedburner.com/~ff/reuters/healthNews?i=wLSynvkl-Wk:DWfhlnFh73Y:F7zBnMyn0Lo" border="0"></img> (http://feeds.reuters.com/~ff/reuters/healthNews?a=wLSynvkl-Wk:DWfhlnFh73Y:F7zBnMyn0Lo) <img src="http://feeds2.feedburner.com/~ff/reuters/healthNews?i=wLSynvkl-Wk:DWfhlnFh73Y:V_sGLiPBpWU" border="0"></img> (http://feeds.reuters.com/~ff/reuters/healthNews?a=wLSynvkl-Wk:DWfhlnFh73Y:V_sGLiPBpWU)
</div><img src="http://feeds2.feedburner.com/~r/reuters/healthNews/~4/wLSynvkl-Wk" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/wLSynvkl-Wk/idUSTRE52S1VO20090329